WIRB-Copernicus Group (WCG), one of the world's leading providers of solutions that measurably improve the quality and efficiency of clinical research, announced an industry-transforming agreement with karmadata, the market leader in clinical trial database and decision support applications.

Under the terms of the agreement, WCG will acquire a suite of proprietary applications designed to facilitate the management of clinical trial data, as well as an exclusive license to use karmadata’s extensive global library of clinical trial investigator and site data.

“Our clients continue to look for ways to accelerate patient access to innovative medicines by increasing the productivity of the drug development process,” commented Donald A. Deieso, PhD, chairman and CEO of WCG. “Through the acquisition of karmadata’s proprietary clinical trials database and big data technologies, we will be able to help them drive an even greater return on investment in the conduct of clinical trials.”

WCG provides the industry’s most comprehensive and quality-driven solutions to increase the speed of clinical trial activation. karmadata is widely recognized as the global leader in the organization and analysis of “big data” in healthcare. The addition of karmadata’s global investigator data to WCG’s existing investigator/site database (WCG InSite) will result in an offering that will provide biopharmaceutical companies and contract research organizations (CROs) with unprecedented information with which to plan and conduct their site feasibility activities.

Added Sean Power, founder and CEO of karmadata, “At karmadata, it is our mission to use data and technology to transform the healthcare industry. We are at a tipping point, and WCG is in a unique position to fundamentally change how sponsors, physicians, and patients experience a clinical trial. WCG has a patient-first mentality that makes me proud to be part of their family. My co-founders, Brendan Kelleher and Yesi Orihuela, are as pleased as I am to announce this exclusive agreement with WCG, and to support the world’s leading clinical trial sponsors and CROs in making smarter, more informed decisions when planning their clinical trials.”